Sunshine Biopharma (SBFM)

$1.43 0.00 (N/A)
Market Cap 6.52M
Revenue (ttm) 34.87M
Net Income (ttm) -5.13M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -14.71%
Debt to Equity Ratio 0.00
Volume 136,600
Avg Vol 108,886
Day's Range N/A - N/A
Shares Out 4.56M
Stochastic %K 38%
Beta 1.46
Analysts Strong Sell
Price Target $7.00

Company Profile

Sunshine Biopharma, Inc. operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates through Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products segments. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pa...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: (954) 330-0684
Address:
333 Las Olas Way, CU4 Suite 433, Fort Lauderdale, United States
LH1975New
LH1975New Sep. 4 at 9:36 PM
$SBFM In 2023, I invested in a small cap stock called Agile Therapeutics (AGRX). I studied their sales pipeline, figures and progress for many months before investing. They had had a history of cash raises, reverse stock splits, dilution and compliance issues. Everyone blamed the CEO, a guy called Altomeri. Lots of longs who were, naturally, very pissed People (perhaps justifiably) thought that a bit of hype could make people thousands overnight. However, I thought they had turned a corner when I invested. Their product (Twirla) was really starting to sell and, although they were not profitable, they had a great growth trajectory and very little debt.The underlying business was doing well. One morning, I woke up to find my depleted investment had almost trebled. What?! Yes, they had been bought out and a definitive merger agreement issued. If I had invested immediately before the buy out, I would have made much more. I am treating SBFM in the same way. Time will tell.
0 · Reply
MB66
MB66 Sep. 4 at 8:32 PM
$SBFM
1 · Reply
Outrun_Sunshine
Outrun_Sunshine Sep. 4 at 8:12 PM
$SBFM Hey. Any other longs want to play a game? What's your share with the highest adjuated cost basis? I had (because I only have the 1 share left after the RS's) some shares from Feb 2021 that had a cost basis of $77,000 adjusted for current share price. Anyone got higher? @Rkb3 come on, man. Tell us how bad you had it! These newbies don't know who you are! Glad I didn't do anything to average down outside of some warrants, and those are long gone. Would have been a total waste of cash.
1 · Reply
djgestates
djgestates Sep. 4 at 8:59 AM
$SBFM Watching this (and I am in DEEP) trade within this tight range for such a long period of time makes it abundantly clear it is not about the ratio of buying to selling, but the broker/MM keeping the bid/ask with this specified range. Why the fuck, then, did the broker not keep it within a specified range before the split, or immediately after the split? What is really happening here?
1 · Reply
Love_To_Learn
Love_To_Learn Sep. 3 at 9:16 PM
$SXTP $SBFM $OST splitting u 3 up!
1 · Reply
Love_To_Learn
Love_To_Learn Sep. 3 at 8:29 PM
$SBFM need to work u a bit for next several trading sessions
0 · Reply
contra7
contra7 Sep. 3 at 1:37 AM
$SBFM Possible buyout scenarios after an exercise of all outstanding warrants using the industry standards for revenue multiples and possible buyout with current float of 4.56 million if warrants are cash settled in buyout negotiations. With Chamoun leaving abruptly, no insider buying at all time lows ( possibly Material Non Public Info due to negotiations), SP detached from current growth trajectory, Slilaty and possibly other company officers with change of control clauses in their contracts a buyout seems very plausible.
3 · Reply
Bat_shtt_crazy
Bat_shtt_crazy Aug. 31 at 12:42 PM
$SBFM https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/assessing-the-biosimilar-void-in-the-us
1 · Reply
MB66
MB66 Aug. 30 at 1:10 AM
$SBFM can this POS get bought out already!?!
0 · Reply
ExecutiveEdge
ExecutiveEdge Aug. 28 at 12:58 PM
TGL has every ingredient for a life-changer. $100M crypto treasury $18 book value 3M float Still unknown. Not for long. $VCIG $SBFM $HCDI $MITQ
0 · Reply
Latest News on SBFM
Sunshine Biopharma Launches NIOPEG(R) Into $10 Billion Biologics Market

Jul 2, 2025, 8:00 AM EDT - 2 months ago

Sunshine Biopharma Launches NIOPEG(R) Into $10 Billion Biologics Market

Sunshine Biopharma Launches Generic Gabapentin for Neuropathic Pain in the Canadian Segment of the Global $1.92 Billion Market

Jun 11, 2025, 8:30 AM EDT - 3 months ago

Sunshine Biopharma Launches Generic Gabapentin for Neuropathic Pain in the Canadian Segment of the Global $1.92 Billion Market

Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year

May 15, 2025, 4:15 PM EDT - 4 months ago

Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year

Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market

May 6, 2025, 8:30 AM EDT - 4 months ago

Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market

Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion

Apr 21, 2025, 8:30 AM EDT - 4 months ago

Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion

Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering

Apr 3, 2025, 10:50 AM EDT - 5 months ago

Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering

Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

Apr 2, 2025, 1:20 PM EDT - 5 months ago

Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug

Apr 2, 2025, 11:35 AM EDT - 5 months ago

Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug

Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer

Apr 2, 2025, 8:00 AM EDT - 5 months ago

Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer

Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year

Apr 1, 2025, 5:09 PM EDT - 5 months ago

Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year

Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada

Mar 24, 2025, 8:00 AM EDT - 5 months ago

Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada

Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market

Mar 10, 2025, 9:00 AM EDT - 6 months ago

Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market

Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT

Jan 21, 2025, 8:00 AM EST - 8 months ago

Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT

Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer

Jan 15, 2025, 8:00 AM EST - 8 months ago

Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer

Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus

Dec 9, 2024, 7:30 AM EST - 9 months ago

Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus

Sunshine Biopharma Launches a New Generic Prescription Drug

Dec 4, 2024, 4:05 PM EST - 9 months ago

Sunshine Biopharma Launches a New Generic Prescription Drug

Sunshine Biopharma Announces Breakthrough Research Results on the Company's K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepatocellular Carcinoma

Dec 2, 2024, 8:00 AM EST - 9 months ago

Sunshine Biopharma Announces Breakthrough Research Results on the Company's K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepatocellular Carcinoma

Sunshine Biopharma Reports 2024 Third Quarter Results: Year-To-Date Revenues Up 54%

Nov 6, 2024, 8:00 AM EST - 10 months ago

Sunshine Biopharma Reports 2024 Third Quarter Results: Year-To-Date Revenues Up 54%

Sunshine Biopharma Launches Two New Generic Prescription Drugs

Sep 26, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Launches Two New Generic Prescription Drugs

Sunshine Biopharma Announces Publication of Significant Coronavirus Research Results in the Journal of Medicinal Chemistry

Sep 4, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Announces Publication of Significant Coronavirus Research Results in the Journal of Medicinal Chemistry

Sunshine Biopharma Has Launched Nine New Generic Prescription Drugs in 2024: Now Marketing Sixty-One Generic Drugs in Canada

Aug 26, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Has Launched Nine New Generic Prescription Drugs in 2024: Now Marketing Sixty-One Generic Drugs in Canada

Sunshine Biopharma Reports 2024 Second Quarter Results: Second QTR Revenues up 67%, YTD Revenues up 61%

Aug 19, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Reports 2024 Second Quarter Results: Second QTR Revenues up 67%, YTD Revenues up 61%

Sunshine Biopharma Announces Reverse Stock Split

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Announces Reverse Stock Split

Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R)

Apr 19, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R)

Sunshine Biopharma Reports Operating Results for the Fiscal Year Ended December 31, 2023

Apr 1, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Reports Operating Results for the Fiscal Year Ended December 31, 2023

Sunshine Biopharma, Inc. Announces Closing of $10.0 Million Underwritten Public Offering

Feb 15, 2024, 9:15 AM EST - 1 year ago

Sunshine Biopharma, Inc. Announces Closing of $10.0 Million Underwritten Public Offering

Sunshine Biopharma, Inc. Announces Pricing of $10.0 Million Underwritten Public Offering

Feb 13, 2024, 9:00 AM EST - 1 year ago

Sunshine Biopharma, Inc. Announces Pricing of $10.0 Million Underwritten Public Offering

Sunshine Biopharma Moves Principal Office to New York City

Dec 4, 2023, 8:30 AM EST - 1 year ago

Sunshine Biopharma Moves Principal Office to New York City

Sunshine Biopharma Reports 2023 Third Quarter Results: Revenues up Significantly Over Last Year Due to a Key Acquisition

Nov 13, 2023, 8:30 AM EST - 1 year ago

Sunshine Biopharma Reports 2023 Third Quarter Results: Revenues up Significantly Over Last Year Due to a Key Acquisition

Sunshine Biopharma Receives 180-Day Extension To Achieve Nasdaq Minimum Bid Compliance

Sep 21, 2023, 9:05 PM EDT - 2 years ago

Sunshine Biopharma Receives 180-Day Extension To Achieve Nasdaq Minimum Bid Compliance

Sunshine Biopharma Reports 2023 Second Quarter Results: Revenues Up 3,600%

Aug 11, 2023, 8:30 AM EDT - 2 years ago

Sunshine Biopharma Reports 2023 Second Quarter Results: Revenues Up 3,600%

Aegis Capital Corp. Acted as Exclusive Placement Agent on a $5.0 Million Private Placement Priced At-the-Market for Sunshine Biopharma, Inc. (NASDAQ:SBFM)

May 16, 2023, 2:15 PM EDT - 2 years ago

Aegis Capital Corp. Acted as Exclusive Placement Agent on a $5.0 Million Private Placement Priced At-the-Market for Sunshine Biopharma, Inc. (NASDAQ:SBFM)

Sunshine Biopharma Announces Closing of $5.0 Million Private Placement Priced At-the-Market

May 16, 2023, 9:58 AM EDT - 2 years ago

Sunshine Biopharma Announces Closing of $5.0 Million Private Placement Priced At-the-Market

Sunshine Biopharma Announces Pricing of $5.0 Million Private Placement Priced At-the-Market

May 12, 2023, 8:00 AM EDT - 2 years ago

Sunshine Biopharma Announces Pricing of $5.0 Million Private Placement Priced At-the-Market

Sunshine Biopharma Reports 2023 First Quarter Results: Revenues Up 2,100%

May 11, 2023, 9:00 AM EDT - 2 years ago

Sunshine Biopharma Reports 2023 First Quarter Results: Revenues Up 2,100%

Sunshine Biopharma Reports Full Year Ended December 31, 2022 Financial Results and Provides Corporate Update

Apr 5, 2023, 8:00 AM EDT - 2 years ago

Sunshine Biopharma Reports Full Year Ended December 31, 2022 Financial Results and Provides Corporate Update

Sunshine Biopharma Signs Exclusive Worldwide License With University of Arizona For PLpro-Based Covid-19 Treatment

Feb 28, 2023, 7:30 AM EST - 2 years ago

Sunshine Biopharma Signs Exclusive Worldwide License With University of Arizona For PLpro-Based Covid-19 Treatment

Sunshine Biopharma Signs Research Agreement With the Jewish General Hospital to Advance the Development of Adva-27a Anticancer Compound

Feb 10, 2023, 7:35 AM EST - 2 years ago

Sunshine Biopharma Signs Research Agreement With the Jewish General Hospital to Advance the Development of Adva-27a Anticancer Compound

Sunshine Biopharma Announces Share Repurchase Program

Jan 19, 2023, 7:30 AM EST - 2 years ago

Sunshine Biopharma Announces Share Repurchase Program

Sunshine Biopharma's Annual Letter to Shareholders

Dec 20, 2022, 8:00 AM EST - 2 years ago

Sunshine Biopharma's Annual Letter to Shareholders

4 Stocks Meeting GuruFocus' Value Screens in December

Dec 5, 2022, 5:46 PM EST - 2 years ago

4 Stocks Meeting GuruFocus' Value Screens in December

RM CACC WFG

Sunshine Biopharma Enters Into a Collaboration Agreement with a Leading Lipid Nanoparticle Formulation Company for Its K1.1 Anticancer mRNA Project

Nov 16, 2022, 8:00 AM EST - 3 years ago

Sunshine Biopharma Enters Into a Collaboration Agreement with a Leading Lipid Nanoparticle Formulation Company for Its K1.1 Anticancer mRNA Project

Sunshine Biopharma Announces the Acquisition of Nora Pharma, Adding $10.7 Million in Revenue

Oct 20, 2022, 8:00 AM EDT - 3 years ago

Sunshine Biopharma Announces the Acquisition of Nora Pharma, Adding $10.7 Million in Revenue

Sunshine Biopharma Files Its Second Quarter Report With the SEC

Aug 4, 2022, 8:00 AM EDT - 3 years ago

Sunshine Biopharma Files Its Second Quarter Report With the SEC

Sunshine Biopharma Increases Support for Anti-Coronavirus Collaborative Research With the University of Arizona

Jul 28, 2022, 8:10 AM EDT - 3 years ago

Sunshine Biopharma Increases Support for Anti-Coronavirus Collaborative Research With the University of Arizona

Sunshine Biopharma: An Opportunity Knocking?

May 9, 2022, 11:03 AM EDT - 3 years ago

Sunshine Biopharma: An Opportunity Knocking?

Sunshine Biopharma, Inc. Announces Closing of $19.5 Million Private Placement Priced At-the-Market

Apr 28, 2022, 4:50 PM EDT - 3 years ago

Sunshine Biopharma, Inc. Announces Closing of $19.5 Million Private Placement Priced At-the-Market

Aegis Capital Corp. acted as Exclusive Placement Agent on a $19.5 Million Private Placement Priced At-the-Market for Sunshine Biopharma Inc. (NASDAQ: SBFM)

Apr 28, 2022, 9:20 AM EDT - 3 years ago

Aegis Capital Corp. acted as Exclusive Placement Agent on a $19.5 Million Private Placement Priced At-the-Market for Sunshine Biopharma Inc. (NASDAQ: SBFM)

Sunshine Biopharma, Inc. Announces Pricing of $19.5 Million Private Placement Priced At-the-Market

Apr 26, 2022, 12:41 AM EDT - 3 years ago

Sunshine Biopharma, Inc. Announces Pricing of $19.5 Million Private Placement Priced At-the-Market

Why Sunshine Biopharma Stock Is Surging

Apr 25, 2022, 10:57 AM EDT - 3 years ago

Why Sunshine Biopharma Stock Is Surging

LH1975New
LH1975New Sep. 4 at 9:36 PM
$SBFM In 2023, I invested in a small cap stock called Agile Therapeutics (AGRX). I studied their sales pipeline, figures and progress for many months before investing. They had had a history of cash raises, reverse stock splits, dilution and compliance issues. Everyone blamed the CEO, a guy called Altomeri. Lots of longs who were, naturally, very pissed People (perhaps justifiably) thought that a bit of hype could make people thousands overnight. However, I thought they had turned a corner when I invested. Their product (Twirla) was really starting to sell and, although they were not profitable, they had a great growth trajectory and very little debt.The underlying business was doing well. One morning, I woke up to find my depleted investment had almost trebled. What?! Yes, they had been bought out and a definitive merger agreement issued. If I had invested immediately before the buy out, I would have made much more. I am treating SBFM in the same way. Time will tell.
0 · Reply
MB66
MB66 Sep. 4 at 8:32 PM
$SBFM
1 · Reply
Outrun_Sunshine
Outrun_Sunshine Sep. 4 at 8:12 PM
$SBFM Hey. Any other longs want to play a game? What's your share with the highest adjuated cost basis? I had (because I only have the 1 share left after the RS's) some shares from Feb 2021 that had a cost basis of $77,000 adjusted for current share price. Anyone got higher? @Rkb3 come on, man. Tell us how bad you had it! These newbies don't know who you are! Glad I didn't do anything to average down outside of some warrants, and those are long gone. Would have been a total waste of cash.
1 · Reply
djgestates
djgestates Sep. 4 at 8:59 AM
$SBFM Watching this (and I am in DEEP) trade within this tight range for such a long period of time makes it abundantly clear it is not about the ratio of buying to selling, but the broker/MM keeping the bid/ask with this specified range. Why the fuck, then, did the broker not keep it within a specified range before the split, or immediately after the split? What is really happening here?
1 · Reply
Love_To_Learn
Love_To_Learn Sep. 3 at 9:16 PM
$SXTP $SBFM $OST splitting u 3 up!
1 · Reply
Love_To_Learn
Love_To_Learn Sep. 3 at 8:29 PM
$SBFM need to work u a bit for next several trading sessions
0 · Reply
contra7
contra7 Sep. 3 at 1:37 AM
$SBFM Possible buyout scenarios after an exercise of all outstanding warrants using the industry standards for revenue multiples and possible buyout with current float of 4.56 million if warrants are cash settled in buyout negotiations. With Chamoun leaving abruptly, no insider buying at all time lows ( possibly Material Non Public Info due to negotiations), SP detached from current growth trajectory, Slilaty and possibly other company officers with change of control clauses in their contracts a buyout seems very plausible.
3 · Reply
Bat_shtt_crazy
Bat_shtt_crazy Aug. 31 at 12:42 PM
$SBFM https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/assessing-the-biosimilar-void-in-the-us
1 · Reply
MB66
MB66 Aug. 30 at 1:10 AM
$SBFM can this POS get bought out already!?!
0 · Reply
ExecutiveEdge
ExecutiveEdge Aug. 28 at 12:58 PM
TGL has every ingredient for a life-changer. $100M crypto treasury $18 book value 3M float Still unknown. Not for long. $VCIG $SBFM $HCDI $MITQ
0 · Reply
LH1975New
LH1975New Aug. 28 at 9:58 AM
$SBFM This is bursting to break out, indicators looking good. Need volume and lots of it. Dear Dr. Slilaty, please throw us a bone! How about an update on how Niopeg sales are doing, perhaps the outlook for 2025 and beyond and/or a definitive forecast of when breakeven is likely based on your projections. Or, how about an interview with you, where you set out the great journey on which SBFM has been and your outlook for the future. If we get the SP beyond $2.07 and people start exercising warrants, then you're going to get a big cash windfall of up to $30M! No need for any further cash raises ever, and you could be forgiven for awarding yourself a healthy bonus. Surely, a WIN WIN?!
1 · Reply
Outrun_Sunshine
Outrun_Sunshine Aug. 27 at 5:16 PM
$SBFM https://youtu.be/ZdBmku2Usz0?si=6Mbf1MPHqkJaypW2
0 · Reply
Sobo90
Sobo90 Aug. 27 at 3:49 PM
$SBFM management was a problem with $AGEN too, until the stock 8x'd in a month. Time your entries and exits better and stop blaming external parameters outside your control. Everyone is a conman until its time for you to be in on the game.
3 · Reply
contra7
contra7 Aug. 27 at 3:09 PM
$SBFM Breakout imminent
1 · Reply
Nuisance
Nuisance Aug. 26 at 7:41 PM
$SBFM 🚨🚨🚨
1 · Reply
kuwaitimilionaire
kuwaitimilionaire Aug. 26 at 7:18 PM
$SBFM the main problem of this company is the management look at the management expenses every quarter in millions they are stealing the revenues this is why institutes are not buying
1 · Reply
contra7
contra7 Aug. 26 at 1:50 PM
$SBFM Usually after an offering closes ( especially a direct offering) the stock rebounds to at least the offering price in the near term. This company closed an offering at $2.07 on 4/3 and nearly 5 months later and after several new generic drug launches in that time span here we are trading at $1.37 🤷🏾‍♂️ go figure
2 · Reply
disdaniel
disdaniel Aug. 25 at 5:38 PM
$SBFM booked a $9K loss on this from selling a half dozen shares held for 2-3 years. might re-invest the ~$9 of proceeds after 30 days
0 · Reply
Suomalainen
Suomalainen Aug. 22 at 1:48 PM
$SBFM We are prisoners of our own device.
1 · Reply
Bat_shtt_crazy
Bat_shtt_crazy Aug. 21 at 7:27 PM
$SBFM Hedge Fund collateral is about to evaporate. Remember yesterday I said something bigs coming? This is it! https://apnews.com/article/china-evergrande-delisted-hong-kong-stock-market-f44e046e6818f61991edc226fb8f9e6f
0 · Reply
BullDurham22
BullDurham22 Aug. 21 at 2:24 PM
$SBFM This stock only knows how to bleed red… it’s literally become a laughing stock 😂
0 · Reply
LH1975New
LH1975New Aug. 21 at 2:16 PM
$SBFM Trading 212 is limiting the buys of SBFM to 5,634. So, if you hold more than that, you can't buy anymore. It has been like this for a while and they say it is due to 'volatility'. However, there are substantially much more volatile stocks, with large swings, which do not have the same restriction. Anyone know why Trading 212 (and other platforms for that matter) do this?
2 · Reply